Innova Captab

Innova Captab EPS

The Earnings per Share (EPS) of Innova Captab (INNOVACAP.NS) as of Nov 22, 2026 is 24.63 INR. In the previous year, Earnings per Share (EPS) was 22.41 INR — a change of 9.87% (higher).

EPS

24.63INR

YoY

9.87%

Last updated:

Earnings per Share (EPS) of Innova Captab is 2026 24.63 INR. Earnings per Share (EPS) of Innova Captab was 2025 22.41 INR. It decreases by 9.87% higher compared to the previous year.

The Innova Captab EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2021
6.03 INR
Jan 1, 2022
11.18 INR
Jan 1, 2023
11.87 INR
Jan 1, 2024
16.47 INR
Jan 1, 2025
22.41 INR
Jan 1, 2026
24.63 INR
Jan 1, 2027 (e)
32.60 INR
Jan 1, 2028 (e)
46.05 INR
The Innova Captab EPS history
YEAREPSYoY
est46.05INR+41.26%
est32.60INR+32.39%
24.63INR+9.87%
22.41INR+36.11%
16.47INR+38.69%
11.87INR+6.24%
11.18INR+85.37%
6.03INR+23.72%
4.87INR-20.26%
6.11INR+192.95%
2.09INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innova Captab stock

Earnings per Share (EPS) of Innova Captab is 24.63 INR in 2026.

Earnings per Share (EPS) of Innova Captab changed from 22.41 INR to 24.63 INR, representing a 9.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Innova Captab since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Innova Captab

All Key Metrics — Innova Captab